DE69626927T2 - Oleat Monoester von Estrogenen zur Behandlung von Fettleibigkeit - Google Patents

Oleat Monoester von Estrogenen zur Behandlung von Fettleibigkeit

Info

Publication number
DE69626927T2
DE69626927T2 DE69626927T DE69626927T DE69626927T2 DE 69626927 T2 DE69626927 T2 DE 69626927T2 DE 69626927 T DE69626927 T DE 69626927T DE 69626927 T DE69626927 T DE 69626927T DE 69626927 T2 DE69626927 T2 DE 69626927T2
Authority
DE
Germany
Prior art keywords
obesity
treatment
group
estrone
monoester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69626927T
Other languages
English (en)
Other versions
DE69626927D1 (de
Inventor
Maria Alemany
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OLEOYL ESTRONE DEVELOPMENTS S
Original Assignee
OLEOYL ESTRONE DEVELOPMENTS S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OLEOYL ESTRONE DEVELOPMENTS S filed Critical OLEOYL ESTRONE DEVELOPMENTS S
Publication of DE69626927D1 publication Critical patent/DE69626927D1/de
Application granted granted Critical
Publication of DE69626927T2 publication Critical patent/DE69626927T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/58—Esters of straight chain acids with eighteen carbon atoms in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
DE69626927T 1995-10-30 1996-10-28 Oleat Monoester von Estrogenen zur Behandlung von Fettleibigkeit Expired - Lifetime DE69626927T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9502101 1995-10-30

Publications (2)

Publication Number Publication Date
DE69626927D1 DE69626927D1 (de) 2003-04-30
DE69626927T2 true DE69626927T2 (de) 2003-11-20

Family

ID=8291993

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69626927T Expired - Lifetime DE69626927T2 (de) 1995-10-30 1996-10-28 Oleat Monoester von Estrogenen zur Behandlung von Fettleibigkeit

Country Status (7)

Country Link
US (1) US5798348A (de)
EP (1) EP0771817B1 (de)
AT (1) ATE235505T1 (de)
DE (1) DE69626927T2 (de)
DK (1) DK0771817T3 (de)
ES (1) ES2192221T3 (de)
PT (1) PT771817E (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
WO1999066915A2 (en) * 1998-06-23 1999-12-29 Southern Illinois University At Carbondale Therapeutic applications of estrogenic carboxylic acids
AU3579200A (en) * 1999-02-26 2000-09-14 Saltech I Goteborg Ab Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1
CA2669753C (en) 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
AU2005242170B2 (en) * 2000-06-26 2008-12-18 The Procter & Gamble Company Compositions and methods for body weight management
US7025984B1 (en) * 2000-06-26 2006-04-11 The Procter & Gamble Company Compositions and methods for body weight management
EP2135611A1 (de) 2001-03-01 2009-12-23 Hollis-Eden Pharmaceuticals Inc. Pregn-5-en-20-yn-3,7,17-triol Derivate zur therapeutischen Verwendung
ES2173049B1 (es) * 2001-03-28 2004-01-16 Oleoyl Estrone Developments S Monoester de acido graso y estrogeno como agente antidiabetico e hipolipemiante.
US6635015B2 (en) 2001-04-20 2003-10-21 The Procter & Gamble Company Body weight management system
US7125568B2 (en) 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
US6821961B2 (en) * 2001-08-24 2004-11-23 Michael P. Girouard Monounsaturated fatty acids of at least 20 carbon atoms and perhydrocyclopentanophenanthrene nucleus combination molecules and their use as weight-loss agents
US20040157816A1 (en) * 2002-08-26 2004-08-12 Girouard Michael P. Monounsaturated fatty acids and perhydrocyclopentanophenanthrene nucleus combination molecules, and their precursors, and the use of all of these as weight-loss agents
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
AU2003294489A1 (en) * 2002-11-20 2004-06-15 Michael P. Girouard Combination of monounsaturated fatty acids and estrogen, and their use
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2515368A1 (en) 2003-02-13 2004-08-26 Luciano Rossetti Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
WO2006110172A2 (en) 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals.Inc. Steroid analogs and characterization and treatment methods
US20060084636A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and serotonin reuptake inhibiting compounds for reducing the body weight of a mammal and compositions containing the same
US20060084637A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US7528791B2 (en) * 2005-08-08 2009-05-05 Wistron Neweb Corporation Antenna structure having a feed element formed on an opposite surface of a substrate from a ground portion and a radiating element
AU2007266475B2 (en) 2006-05-30 2009-12-03 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
WO2008147373A2 (en) * 2006-06-26 2008-12-04 Manhattan Pharmaceuticals, Inc. Methods and compositions for reducing body weight using an estrogen fatty ester in an oil
DK2359808T3 (da) 2006-08-09 2013-08-05 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelaggregater
ES2302449B1 (es) * 2006-10-30 2009-06-12 Oleoyl-Estrone Developments, S.L. Monoesteres de estrogenos con acido linoleico conjugado y usos de los mismos.
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
EP2085089A1 (de) * 2008-02-01 2009-08-05 KTB-Tumorforschungs GmbH Phospholipide mit Omega-3-Fettsäuren zur Behandlung von Übergewicht, Adipositas und Suchtverhalten
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
ES2650667T3 (es) 2009-09-28 2018-01-19 Intarcia Therapeutics, Inc Rápido establecimiento y/o terminación de la administración sustancial de fármaco en estado estacionario
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20140378424A1 (en) * 2011-12-30 2014-12-25 Rosscreening, Inc. Estrogen receptor modulators for reducing body weight
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US10836788B2 (en) 2019-02-05 2020-11-17 SD Chem, Inc. Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2265976A (en) * 1937-10-25 1941-12-09 Schering Corp Tertiary alcohols of the estrane series and their derivatives and a process for their manufacture
GB531178A (en) * 1938-07-02 1940-12-31 Chem Ind Basel Manufacture of new esters of the oxy-stilbene series
JPH0610127B2 (ja) * 1985-02-09 1994-02-09 ライオン株式会社 養毛料
US4617298A (en) * 1985-10-22 1986-10-14 University Of Florida Method and compositions for weight control

Also Published As

Publication number Publication date
ES2192221T3 (es) 2003-10-01
DK0771817T3 (da) 2003-07-28
PT771817E (pt) 2003-06-30
ATE235505T1 (de) 2003-04-15
EP0771817A2 (de) 1997-05-07
DE69626927D1 (de) 2003-04-30
US5798348A (en) 1998-08-25
EP0771817B1 (de) 2003-03-26
EP0771817A3 (de) 1999-04-14

Similar Documents

Publication Publication Date Title
DE69626927D1 (de) Oleat Monoester von Estrogenen zur Behandlung von Fettleibigkeit
EP0196268B1 (de) Estriolester
Zampolli et al. Contrasting effect of fish oil supplementation on the development of atherosclerosis in murine models
US5034414A (en) Liquid emulsion for transfusion
ES2074734T3 (es) Utilizacion de composiciones a base de alcoholes grasos, para la preparacion de emulsiones; procedimiento de preparacion de emulsiones y emulsiones asi obtenidas.
JPH0336567B2 (de)
Wallach et al. Studies on the arachidonic acid cascade—I: Inhibition of phospholipase A2in vitro and in vivo by several novel series of inhibitor compounds
RU2007108771A (ru) Способы лечения, требующие фитокомпонентов
JPH02189394A (ja) 油脂組成物
EP0366480A3 (de) Verfahren und Mittel zur Behandlung der Alzheimer-Krankheit, verwandter Demenzen und Epilepsie
DE69117029T2 (de) Verfahren zur herstellung eines durch einbau einer lipophilen wirksubstanz modifizierten lipoproteins
Larue et al. Effect of the removal of olfactory bulbs upon hyperphagia and obesity induced in rats by VMH lesion
HUP0001137A2 (hu) Bőrápoló szer
ATE93722T1 (de) Omega-3-fettsaeurenhaltige fettemulsion zur endotrachealen applikation, ihre herstellung und anwendung.
JPS5517328A (en) Insulin-containing emulsion and its preparation
KR910005872A (ko) 간염 예방 치료제
WO2004045560A3 (en) Combination of monounsaturated fatty acids and estogen, and their use
RU95108891A (ru) Фармацевтическая эмульсия, содержащая биологически активные стероиды, способ получения эмульсии, применение эмульсии
Ayyad et al. Palmitic acid enhances cholesterol gallstone incidence in Sasco hamsters fed cholesterol enriched diets
KR920021151A (ko) 면역억제특성을 갖는 약제학적 조성물을 제조하기 위한 인지질 유도체의 용도
Brattsand The effect of niceritrol (pentaerythritoltetra-nicotinate) and clofibrate upon hyperlipemia and atherosclerosis induced in rabbits by cholesterol-free semisynthetic diets
WO2002049654A1 (en) Shark meat extract
US5420161A (en) Doisynolic acid type compounds as weight and appetite suppressing and control agents
JP3996342B2 (ja) 油脂組成物
Draper et al. Malondialdehyde derivatives in urine

Legal Events

Date Code Title Description
8364 No opposition during term of opposition